The EYLEA (aflibercept) injection was approved by the Food and Drug Administration for the treatment of neovascular (wet) age-related macular degeneration (AMD).
Macular degeneration is diagnosed as either dry (non-vascular) or wet (vascular); the wet form usually leads to more serious vision loss.
The Apothecary Shops ophthalmology national director Jim Rehovsky said they work directly with the administering physician and the insurance provider and thus can better serve their customers prescribed with EYLEA.